5-(甲氧基羰基)-4-(三氟甲基)嘧啶-2-肼 | 175137-28-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-(甲氧基羰基)-4-(三氟甲基)嘧啶-2-肼
• 中文别名: 5-甲氧基羰基-4-三氟甲基嘧啶-2-肼
• 英文名称: methyl 2-hydrazinyl-4-(trifluoromethyl)pyrimidine-5-carboxylate
• 英文别名: 5-methoxycarbonyl-4-(trifluoromethyl)pyrimidin-2-yl hydrazine
• CAS: 175137-28-7
• 化学式: C₇H₇F₃N₄O₂
• mdl: MFCD00068147
• 分子量: 236.153
• InChiKey: LIMNVGGTQCLNNP-UHFFFAOYSA-N

物化性质

• 熔点：
  132 °C
• 沸点：
  266.7±50.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  90.1
• 氢给体数：
  2
• 氢受体数：
  9

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090

SDS

Name:	Methyl 2-hydrazino-4-(trifluoromethyl)pyrimidine-5-carboxylate 95+% Material Safety Data Sheet
Synonym:
CAS:	175137-28-7

Section 1 - Chemical Product MSDS Name:Methyl 2-hydrazino-4-(trifluoromethyl)pyrimidine-5-carboxylate 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175137-28-7	Methyl 2-hydrazino-4-(trifluoromethyl)	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175137-28-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 132 - 134 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7F3N4O2
Molecular Weight: 236

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175137-28-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 2-hydrazino-4-(trifluoromethyl)pyrimidine-5-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 175137-28-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175137-28-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175137-28-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(甲氧基羰基)-4-(三氟甲基)嘧啶-2-肼 在 对甲苯磺酸 、 3-戊酮 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 0.17h， 生成 methyl 3-methyl-6-(trifluoromethyl)-4-(trimethylsilyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
  参考文献：
  名称：

  通过分子内 Diels-Alder 反应从 2-腙基嘧啶合成 7-氮杂-吲唑的预变形活化嘧啶

  摘要：

  在与烯烃和炔烃的 Diels-Alder 环加成反应中，嘧啶几乎是非反应性的伙伴，之前仅报道过在剧烈条件下的反应。我们描述了 2-腙基嘧啶，很容易从市售的 2-卤代嘧啶中分两步获得，如何通过三氟乙酰化异常活化。这允许在非常温和的反应条件下进行狄尔斯-阿尔德环加成反应，从而产生大量多样化的氮杂吲唑，这是药物化学中普遍存在的支架。该反应是通用的、可扩展的并且具有优异的官能团耐受性。拜耳 Vericiguat 关键中间体的直接合成说明了这种环加成策略的潜力。

  DOI：

  10.1021/jacs.9b07037
• 作为产物：
  描述：

  2-氯-4-三氟甲基嘧啶-5-羧酸甲酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 以100%的产率得到5-(甲氧基羰基)-4-(三氟甲基)嘧啶-2-肼
  参考文献：
  名称：

  通过分子内 Diels-Alder 反应从 2-腙基嘧啶合成 7-氮杂-吲唑的预变形活化嘧啶

  摘要：

  在与烯烃和炔烃的 Diels-Alder 环加成反应中，嘧啶几乎是非反应性的伙伴，之前仅报道过在剧烈条件下的反应。我们描述了 2-腙基嘧啶，很容易从市售的 2-卤代嘧啶中分两步获得，如何通过三氟乙酰化异常活化。这允许在非常温和的反应条件下进行狄尔斯-阿尔德环加成反应，从而产生大量多样化的氮杂吲唑，这是药物化学中普遍存在的支架。该反应是通用的、可扩展的并且具有优异的官能团耐受性。拜耳 Vericiguat 关键中间体的直接合成说明了这种环加成策略的潜力。

  DOI：

  10.1021/jacs.9b07037

文献信息

• Solid-phase versus solution synthesis of asymmetrically disubstituted furazano[3,4-b]pyrazines
  作者：E. Fernández、S. Garcı́a-Ochoa、S. Huss、A. Mallo、J.M. Bueno、F. Micheli、A. Paio、E. Piga、P. Zarantonello

  DOI：10.1016/s0040-4039(02)00913-9

  日期：2002.7

  Herein we describe a straightforward solid-phase synthesis directed towards the preparation of families of asymmetrically disubstituted furazano[3,4-b]pyrazines by stepwise displacement of the two chlorine atoms in 5,6-dichlorofurazano[3,4-b]pyrazine by nucleophiles. This synthesis has avoided selectivity problems found in solution chemistry.

  本文中，我们描述针对对称二取代furazano [3,4的家庭的制备简单的固相合成b在5,6- dichlorofurazano [3,4]由两个氯原子的逐步位移吡嗪b ]吡嗪通过亲核试剂。该合成避免了在溶液化学中发现的选择性问题。
• Hydrazide and alkoxyamide angiogenesis inhibitors
  申请人：——

  公开号：US20020002152A1

  公开（公告）日：2002-01-03

  Compounds having the formula 1 are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

  具有以下化学式的化合物是蛋氨酸氨肽酶2型（MetAP2）抑制剂，对抑制血管生成有用。还公开了抑制MetAP2的组合物和在哺乳动物中抑制血管生成的方法。
• [EN] HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS<br/>[FR] INHIBITEURS D'ANGIOGENESE A BASE D'HYDRAZIDE ET D'ALCOXYAMIDE
  申请人：ABBOTT LAB

  公开号：WO2001079157A1

  公开（公告）日：2001-10-25

  Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

  具有公式的化合物是蛋氨酸氨肽酶2型（MetAP2）抑制剂，并且对于抑制血管生成具有用处。还披露了MetAP2抑制剂组合物和在哺乳动物中抑制血管生成的方法。
• [EN] PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS<br/>[FR] CARBOXYLATES DE PYRIMIDINE ET COMPOSES APPARENTES ET PROCEDES POUR LE TRAITEMENT D'ETATS INFLAMMATOIRES
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：WO1998038171A1

  公开（公告）日：1998-09-03

  (EN) Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition. (FR) Cette invention se rapporte à des composés utiles comme agents anti-inflammatoires en général et, plus particulièrement, pour la prévention et/ou le traitement de maladies immuno-inflammatoires et auto-immunes. Ces composés sont des composés contenant des pyrinidines et, dans un mode de réalisation, ce sont des esters de ces mêmes composés. Cette invention présente des procédés permettant de prévenir et/ou de traiter des états inflammatoires en administrant à un animal nécessitant un tel traitement une quantité efficace d'un composé de cette invention, de préférence sous la forme d'une composition pharmaceutique.

  具有抗炎作用的化合物，一般用于预防和/或治疗免疫炎症和自身免疫性疾病。这些化合物是含有嘧啶的化合物，其中一种实施方式是它们的酯类。该发明还揭示了通过向需要治疗的动物中投与本发明化合物的有效量，特别是以药物组成的形式，来预防和/或治疗炎症状况的方法。
• [EN] PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS<br/>[FR] CARBOXYLATES DE PYRIMIDINE, COMPOSES CONNEXES ET METHODES DE TRAITEMENT DES ETATS INFLAMMATOIRES
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：WO1997009325A1

  公开（公告）日：1997-03-13

  (EN) Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immuno-inflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.(FR) Composés s'avérant utiles comme agents anti-inflammatoires d'une manière générale et, plus spécifiquement, pour la prévention et/ou le traitement des maladies immuno-inflammatoires et auto-immunes. Ces composés sont des composés contenant de la pyrimidine et, dans un mode de réalisation, sont des esters de celle-ci. L'invention porte également sur des méthodes de prévention et/ou de traitement des états inflammatoires par administration à un animal en ayant besoin d'une dose efficace d'un composé de cette invention, de préférence sous forme d'une composition pharmaceutique.

  (中)本发明揭示了作为抗炎剂的化合物，通常用于预防和/或治疗免疫炎症和自身免疫性疾病。这些化合物是含有嘧啶的化合物，在一种实施方式中，是其酯类。本发明还揭示了通过向需要的动物施用本发明的化合物的有效量，特别是以药物组合物的形式，来预防和/或治疗炎症状况的方法。